![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:8402M Healthcare Enterprise Group PLC 27 May 2005 Healthcare Enterprise Group PLC ("HCEG" or the "Company") HCEG signs first distribution agreement for Chinese market HCEG, the international healthcare products and services Company, has agreed its first distribution contract in China, with a major Chinese distributor, Chung Fai International Development Company ("Chung Fai"). The agreement covers the Beijing area of China with an initial $7 million contract for the distribution of its Ebiox range of instrument decontamination products. Chung Fai is one of China's leading distributors with access to 27,000 of the 67,000 hospitals in China. Chung Fai distributes products aimed at the sterile services market in China for a number of major international companies including 3M (USA), Medisafe (USA), as well as representing the endoscopic devices of Tekno (Germany) and the medical imaging products of Kodak (USA). Ebiox Limited, a wholly owned subsidiary of HCEG, has a range of proprietary cleansing and decontamination products for use in healthcare and other industries. The first product group to be promoted by Chung Fai will be the instrument decontamination range with sales expected to commence within the next 6 months. Marketing will begin immediately with Ebiox sponsoring three high-level sterile services conferences; one in Ghuanzou in June, one in Beijing in August and one in Shanghai in September. Thereafter the marketing for Ebiox hand cleansing products and surface disinfectants will commence with further distribution contracts entered into for these products at the appropriate time. Ebiox has already identified two premier manufacturing facilities to supply products in China. HCEG is also in discussions with other partners regarding distribution agreements for other areas in China. Stuart Bruck, Executive Chairman, Healthcare Enterprise Group PLC, commented: "There has been significant interest in our products from China in relation to their ability to control the spread of Avian Flu, SARS and HIV. "Chung Fai gives us a key foothold in the capital city of one of the world's largest markets. The total addressable market for Ebiox in China is estimated to be around US$2 billion. We are already in discussion with further potential partners to cover other geographical areas in China. "We expect revenues to accrue from this agreement towards the end of this calendar year, as the products attain registration with the Chinese FDA. We have experienced a great willingness from the authorities to fast-track this process wherever possible throughout the Asian region." 27 May 2005 Enquiries: Healthcare Enterprise Group 020 7351 7500 John Bradshaw, Group Finance Director Gordon Wood, Group Chief Executive College Hill 020 7457 2020 Corinna Dorward /Adrian Duffield Notes Healthcare Enterprise Group PLC HCEG is quoted on the UK AIM stock market with its head office in London. HCEG is a business engaged in medical product distribution, occupational health, first aid and medical consultancy markets. These businesses underpin a range of innovative medical devices, which will be introduced to the market via HCEG's own distribution network on an international basis. This information is provided by RNS The company news service from the London Stock Exchange END AGRPKAKKCBKDNPB
1 Year Healthcare Enterprise Chart |
1 Month Healthcare Enterprise Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions